PAVmed (NASDAQ:PAVM) Share Price Crosses Below 50 Day Moving Average – Here’s Why

Posted by Stanley Muller on May 24th, 2026

Shares of PAVmed Inc. (NASDAQ:PAVM – Get Free Report) passed below its 50-day moving average during trading on Friday . The stock has a 50-day moving average of $8.72 and traded as low as $6.11. PAVmed shares last traded at $6.39, with a volume of 6,460 shares.

Analysts Set New Price Targets

Several brokerages have recently commented on PAVM. Weiss Ratings restated a “sell (d)” rating on shares of PAVmed in a report on Tuesday, April 21st. Ascendiant Capital Markets decreased their target price on PAVmed from $510.00 to $65.00 and set a “buy” rating on the stock in a report on Thursday, April 9th. Finally, Wall Street Zen upgraded PAVmed from a “sell” rating to a “hold” rating in a report on Saturday, April 4th. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, PAVmed has a consensus rating of “Hold” and a consensus price target of $65.00.

Read Our Latest Analysis on PAVM

PAVmed Stock Up 0.6%

The firm has a fifty day moving average price of $8.72 and a 200 day moving average price of $9.30. The company has a quick ratio of 2.02, a current ratio of 2.02 and a debt-to-equity ratio of 0.70. The company has a market cap of $6.39 million, a P/E ratio of -0.17 and a beta of 0.64.

PAVmed (NASDAQ:PAVM – Get Free Report) last announced its earnings results on Friday, May 15th. The company reported ($1.17) EPS for the quarter, missing the consensus estimate of ($0.69) by ($0.48). PAVmed had a negative return on equity of 146.19% and a negative net margin of 21,914.12%.The business had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.07 million. Equities research analysts forecast that PAVmed Inc. will post -3.19 earnings per share for the current year.

Hedge Funds Weigh In On PAVmed

A hedge fund recently raised its stake in PAVmed stock. Jane Street Group LLC increased its position in shares of PAVmed Inc. (NASDAQ:PAVM – Free Report) by 392.9% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 52,676 shares of the company’s stock after acquiring an additional 41,990 shares during the quarter. Jane Street Group LLC owned about 0.31% of PAVmed worth $32,000 at the end of the most recent quarter. Institutional investors own 19.93% of the company’s stock.

About PAVmed

(Get Free Report)

PAVmed Inc is a clinical-stage medical technology company focused on acquiring, developing and commercializing innovative medical devices aimed primarily at gastrointestinal endoscopy and related therapeutic areas. Its portfolio includes FDA-cleared products such as EsoFLIP® Distensibility System for the treatment of esophageal strictures and MUSE™ (Medigus Ultrasonic Surgical Endostapler) for endoscopic fundoplication in gastroesophageal reflux disease (GERD). In addition to its gastrointestinal franchise, PAVmed is advancing early-stage programs targeting indications in oncology, urology and dermatology.

Founded in 2012, PAVmed has built its pipeline through internal research and development as well as strategic collaborations and acquisitions.